title: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
abstract: Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.
authors.affiliation: Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, Doha, State of Qatar. jha01@hmc.org.qa
authors.forename: Jassim Al
authors.initials: JA
authors.lastname: Suwaidi
authors.forename: Amar M
authors.initials: AM
authors.lastname: Salam